Nutriband Inc.

Nutriband Inc.

NTRB·NASDAQ

$4.15

-0.72%
HealthcareBiotechnology

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

At a Glance

Live Snapshot
Market Cap$50.45M
EPS-0.9900
P/E Ratio-4.19
Earnings Date04/27/2026

ntrb

Other Current Liabilities

Last Annual Value

0.00

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Nutriband Inc.

Nutriband Inc. Competitors Analysis of Other Current Liabilities

NTRB · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
0.00
N/AN/AN/A 
10.29M
20.3%21.3%N/A
4.86M
-5.1%24.3%25.2%
XBIT logo
XBiotech Inc.
NASDAQ:XBIT
6.32M
124.0%47.5%28.3%
12.21M
46.8%78.9%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
13.61M
25.2%27.6%-12.1%
2.26M
17.8%468.9%N/A
-1.03M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-2.98M
N/AN/AN/A
IMA logo
ImageneBio Inc
NASDAQ:IMA
7.53M
30.4%21.6%N/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
20.01M
4.6%88.0%22.9%
Nutriband Inc.

Nutriband Inc. Fair Value Envelope

NTRB · NASDAQ

Our analysis suggests that NTRB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.15, this represents a potential HIDDEN relative to our calculated worth for Nutriband Inc..

Intrinsic Value
Current Price: $4.15